Home › Research › Treatments
Efficacy of Bacopa monnieri (Linn.) on Cognitive Function and Alterations in Blood Metabolites in Patients With Amnestic Mild Cognitive Impairment and Early Alzheimer Disease: Protocol for an Exploratory Double-Blind, Randomized, Placebo-Controlled Trial
Dwivedi A, Anjali A, Narzari H, Kumar Y, Sharma HP, Dubey A, Nilima N, Rajan R et al.. JMIR research protocols, 2026-02-25
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Bacopa consumption is known to enhance cognitive performance in healthy individuals and is associated with alterations in pathways related to branched-chain and aromatic amino acid biosynthesis. Results The study was funded in October 2023, and the first participant was enrolled in April 2024. Data collection will conclude in June 2026, after which data analysis will begin and be completed by September 2026, with primary findings targeted for publication in spring 2027.
What this study adds
Evidence grade: High
The record lists 76 participants. This is a protocol for an ongoing trial of Bacopa monnieri in people with amnestic mild cognitive impairment and early Alzheimer's disease. Reported effect size: 88.3%; 78.3%; 48.3%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Dwivedi, A., Anjali, A., Narzari, H., Kumar, Y., Sharma, H. P., Dubey, A., et al. (2026). Efficacy of Bacopa monnieri (Linn.) on Cognitive Function and Alterations in Blood Metabolites in Patients With Amnestic Mild Cognitive Impairment and Early Alzheimer Disease: Protocol for an Exploratory Double-Blind, Randomized, Placebo-Controlled Trial. JMIR research protocols. https://doi.org/10.2196/82891
Vancouver
Dwivedi A, Anjali A, Narzari H, Kumar Y, Sharma HP, Dubey A, et al. Efficacy of Bacopa monnieri (Linn.) on Cognitive Function and Alterations in Blood Metabolites in Patients With Amnestic Mild Cognitive Impairment and Early Alzheimer Disease: Protocol for an Exploratory Double-Blind, Randomized, Placebo-Controlled Trial. JMIR research protocols. 2026. doi:10.2196/82891. PMID: 41740144.
BibTeX
@article{dwivedi2026-41740144,
author = {Dwivedi, A. and Anjali, A. and Narzari, H. and Kumar, Y. and Sharma, H. P. and Dubey, A. and Nilima, N. and Rajan, R. and others},
title = {{Efficacy of Bacopa monnieri (Linn.) on Cognitive Function and Alterations in Blood Metabolites in Patients With Amnestic Mild Cognitive Impairment and Early Alzheimer Disease: Protocol for an Exploratory Double-Blind, Randomized, Placebo-Controlled Trial}},
journal = {JMIR research protocols},
year = {2026},
doi = {10.2196/82891},
pmid = {41740144},
url = {https://doi.org/10.2196/82891}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Bacopa consumption is known to enhance cognitive performance in healthy individuals and is associated with alterations in pathways related to branched-chain and aromatic amino acid biosynthesis.
- Results The study was funded in October 2023, and the first participant was enrolled in April 2024.
- Data collection will conclude in June 2026, after which data analysis will begin and be completed by September 2026, with primary findings targeted for publication in spring 2027.
Why it matters
This is a protocol for an ongoing trial of Bacopa monnieri in people with amnestic mild cognitive impairment and early Alzheimer's disease. No results are available yet, so nothing can be concluded about its effects.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants76
- Effect size88.3%; 78.3%; 48.3%
- Evidence strengthHigh
How this study scored 52/100
Published in a peer-reviewed journal. Scored zero for study design because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 50 of the 96 points we could judge it on, which is 52 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (JMIR research protocols) |
| Journal's citation record | 0 / 4 | JMIR Research Protocols: journal h-index 62 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 1 / 4 | 76 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | 2 / 7 | Cited 5 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.5 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 6 / 6 | Cited 49.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 5 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Anu Gupta holds only 1 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 0 / 3 | All India Institute of Medical Sciences: institution h-index 440 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41740144) |
| Free to read | 2 / 2 | Free to read |
| Points | 50 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 50 of the 96 points we could judge it on is 52 out of 100. |
| Total | 52 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.